CLIMB THAL-111 — the beta thalassemia trial behind the Casgevy approval
官方名称: A Safety and Efficacy Study Evaluating CTX001 in Subjects With Transfusion-Dependent β-Thalassemia
CompletedPhase II/IIINCT03655678
Clinical researchBeing tested in people in registered clinical trials. Being in trials is not evidence that a treatment works or is safe.
本试验正在测试什么
The companion study to the sickle cell trial, in people with beta thalassemia who needed regular blood transfusions to live. The question was whether editing their own stem cells would let them stop. Most participants became transfusion-independent.
An open-label, single-arm Phase 2/3 study of exagamglogene autotemcel in patients aged 12–35 with transfusion-dependent beta thalassemia. The primary endpoint was transfusion independence, defined as maintaining a weighted average haemoglobin of at least 9 g/dL without transfusion for at least 12 consecutive months.